BUSINESS

Kyowa Kirin Sales Slip 1.9% in 2018, but Profit Up on One-Off Factors

February 6, 2019
Kyowa Hakko Kirin’s group revenue skidded 1.9% to 346,531 million yen in 2018 as growth of new drugs overseas failed to counter sluggish sales in Japan, where the company suffered drug price cuts in April and generic penetration. Outside Japan,…

To read the full story

Related Article

BUSINESS

By Reiji Anasako

Kyowa Hakko Kirin’s first and only Rituxan (rituximab) biosimilar in Japan is showing a faster-than-expected uptake in the market, with the company racking up 4.3 billion yen from the cancer drug in 2018, far beyond its initial 3.2 billion yen…

Members of a key reimbursement policy panel appear to be becoming more and more open to the industry’s call for…

By Takashi Ebisawa

A series of drug makers restructured or sold off production facilities in FY2018. Others dissolved or withdrew from the pharmaceutical business altogether. The entry of generics and transfer of products triggered these moves, but the underlying factor was the impact…

By Philip Carrigan

With a cursory glance, recruitment is easily defined. We’re here to help place candidates into the vacancies our clients need to fill. Armed with a pen and paper, you could even map out the process.• We study the market• We…